

### Remarks

Pending claims examined in the March 26, 2007 Office Action were 1-9, 13, 15, 18-25, 34, 58, 97, 125, 159, 172, 173, 180, 191-194, 203 and 214. This Amendment and Reply newly cancels claims 34, 159, 172-173, 180, 192-194, 203, and 213-214 and adds claims 262-300. Pending claims are now 1-9, 13, 15, 18-25, 58, 97, 125 and 262-300. The claim cancellations are made without prejudice or disclaimer.

### Election/Restriction

A restriction requirement was imposed in the Office Action of March 26, 2007 requiring restriction of the claims to one of the following groups:

Group I: Claims 1-9, 13, 15, 18-25, 58, 97 and 125, drawn to methods of inducing mutations in a gene in a eukaryotic cell wherein the method comprises expressing a transgenic activation-induced cytidine deaminase (AID) gene in the cell;

Group II: Claim 34, drawn to methods of determining the effect of a mutation in a gene encoding a protein on the phenotype of the protein in a eukaryotic cell;

Group III: Claims 159, 172-173, 180, 192-194, 203 and 213-214, drawn to recombinant eukaryotic cells comprising a transgenic, inducible AID gene.

Applicants elect Group I, methods of inducing mutations, without traverse. Claims reading on Group I are 1-9, 13, 15, 18-25, 58, 97, 125 and 262-300, i.e., all currently pending claims.

### Supplemental Information Disclosure Statement

Pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98, applicants enclose herewith Form PTO/SB/08A, along with the one non-U.S. patent publication cited therein. The three references cited therein were cited in the International Search Report (ISR) of the international phase of this application, PCT/US03/01149. A copy of the ISR is provided herewith.


Conclusion

Applicants have previously paid for 34 total claims and 9 independent claims. With the instant amendments, there are 61 total claims and 4 independent claims. Applicants provide a check for \$1350 herewith to pay for the 27 claims currently pending beyond the 34 claims already paid for. Applicants believe that no additional fee is required with this Amendment and Reply. However, if there are any fees required to maintain pendency of this application, authorization is hereby given to charge that fee to Deposit Account No. 01-1785. Excess payment can be credited to Deposit Account 01-1785.

Respectfully submitted

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicant  
90 Park Avenue  
New York, NY 10016  
(212) 336-8000

Dated: New York, New York  
April 17, 2007

By:   
Elie H. Gendloff  
Registration No.: 44,704

04/20/2007 GFREY1 00000070 10501628

01 FC:2615  
02 FC:1206

675.00 OP  
675.00 OP